MICROBIOME & PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE ROTTERDAM, THE NETHERLANDS 18-20 May 2020
#MicrobiomeForum
www.global-engage.com WARM WELCOME
Global Engage is pleased to announce the 7th Microbiome & Probiotics R&D and Business Collaboration Forum, due to be held for 3 days between May 18-20 2020 at the Postillion Convention Centre, World Trade Centre, Rotterdam.
This world-renowned event brings together more than 400 industry, academic, and investment leaders to discuss the most cutting-edge microbiome and probiotics research, challenges and opportunities in moving research towards commercialisation, and partnerships and collaborations. This year, the meeting will focus is on the dedicated microbiome themes outlined below as well as the tracks dedicated to Pro/Prebiotics and Skin & Cosmeceuticals:
Microbiome & Probiotics R&D and Business Collaboration Forum Room 1 Room 2 Room 3 Room 4 IBD, Colitis, Probiotics & Skin & Day 1 Women’s Health Metabolic Diseases Prebiotics Cosmeceuticals Diagnostics & Personalised Skin & Day 2 Gut-Brain Axis Microbiome Biobanks Nutrition Cosmeceuticals Business Collaboration Microbiome Tools Day 3 Cancer - Regulations and Early Life and Infant and Technologies Investment
With a 100-strong speaker faculty, expert-led roundtables and interactive panel sessions, this year’s event promises to deliver ample content on the key challenges faced by both researchers and product developers, and the strategies that turn science into viable products with the backing of investors to fund the transition; and with over 8 hours of networking time, there will be numerous opportunities to showcase your work and to broaden your connections in this fast-growing field. The event is widely recognized for its comprehensive agenda and is gaining a fantastic reputation as the number one microbiome networking event. If you’re looking to learn more from the top scientists in the microbiome and probiotic space, to showcase exciting developments in your research, or to seek partnerships and funding within the industry, then this meeting is not to be missed.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 EVENT SP0NSORS
Platinum Sponsor
Gold Sponsors
Silver Sponsors
Bronze Sponsor
Other Exibitors & Sponsors
Pen & Pad Sponsor Content Sponsors
SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE For more details contact Gavin Hambrook: [email protected] or call +44 (0) 7538 368 764
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 MICROBIOME SPEAKERS
KAREN NELSON SCOTT OLESEN NICOLETTA DI SIMONE President, J. Craig Venter Scientific Director, OpenBiome Professor Obstetrics and Institute, USA Gynecology, Catholic University, Rome, Italy
PAUL WILMES EVELIINA MUNUKKA GEOFF BRIGGS Associate Professor of Research Director, Turko Technology Scout (Devices & Systems Ecology, University Microbiome Biobank, University Diagnostics), Walgreen Boots of Luxembourg of Turku, Finland Alliance
GREGORY BUCK EMERAN MAYER YEMI ADESOKAN Professor, Microbiology Director, UCLA Co-Founder and CSO, & Immunology & GNUbiotics Computer Science, Virginia Commonwealth University AARON DEL DUCA OLGA A. PARTINGTON RIKKE NIELSEN Head, Microbiome Platform Counsel, Sterne, Kessler, CEO and Founder, Beo Goldstein & Fox P.L.L.C. Therapeutics
ALETTA KRANEVELD LARS ENGSTRAND DUCCIO CAVALIERI Professor Interdisciplinary Professor, Director Clinical Professor of Microbiology, Translational Pharmacology, Genomics Facility & Centre University of Florence University of Utrecht, The for Translational Microbiome Netherlands Research, Karolinska Instituet, Sweden FLORENCE SEJOURNE MOMO VUYISICH CEO, Da Volterra CSO, Viome, USA KRISTIN WANNERBERGER Director R&D Alliance Management, Ferring LIISA LEHTORANTA PIERRE LESTAGE Pharmaceuticals, Switzerland R&D Manager, Nutrition & CEO, Neribiom, France Biosciences, DuPont HOK BING THIO Erasmus University Medical Center HENRIK BJØRN FINN TERJE HEGGE NIELSEN CTO and Head of Operations, CSO, Clinical Microbiomics Genetic Analysis AS MALCOLM KENDALL Co-Founder & CEO, Microbiome Insights, Inc YUANYUAN CHEN GEORGE TETZ Sales Director, Novogene CEO, Human Microbiology Institute ERIC DE LA FORTELLE Venture Partner, Seventure Partners SENIOR KRISTOFER COOK REPRESENTATIVE CEO, Carbiotix DNA Genotek ROMAIN DAILLÈRE Head of Preclinical Research, EverImmune MARIA AKERMAN BENJAMIN LELOUVIER Director Process R&D, CSO, Vaiomer Oxthera, Sweden SIMONE MACCAFERRI Senior Research Advisor, Bioeconomy - Research and MARIE DRAGO OLA TUVESSON Competitive Funding Division, Founder, Gallinée Head of Process Development Alma Mater Studiorum and Support, Cobra Biologics Università di Bologna, Italy
EDWIN ABELN EDWARD GREEN FRANCOIS BIDET Senior Business Development Chief Executive, CHAIN Vice-President of Business Manager, TNO Biotechnology Ltd. Development, CSP Technologies COLETTE SHORTT HANA JANEBDAR SARITA DAM Director Global Regulatory Founder and CEO, Juno Bio PhD Candidate in Translational Affairs, J&J Consumer Psychiatry, Radboud University Medical Centre Nijmegen
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 MICROBIOME SPEAKERS
LISA MACFARLANE ARNE MATERNA QUN WANG Co-Founder, The Gut Stuff Vice President of Product, Primary Reviewer, Office of CosmosID Vaccines Research and Review Center for Biologics Evaluation and Research, U. S. Food and ALANA MACFARLANE FRANCO VICARIOTTO Drug Administration Co-Founder, The Gut Stuff Specialist Obstetrics and Gynecology, Senior consultant of DAVID HUGHES San PIO X Hospital Milan, Italy Lecturer / Assistant Professor, Cancer Biology ROBERTO GRAU KAITLIN WADE and Therapeutics Group, UCD Assistant Professor, School of Elizabeth Blackwell Institute Conway Institute, University Biochemistry and Pharmacy, Research Fellow in Integrative College Dublin National University of Rosario, Epidemiology, University of Argentina Bristol, UK
JULIA KAPPEL SANDRINE CLAUS Customer Success Associate, CSO, LNC Therapeutics Zymo Biomics
PROBIOTICS SPEAKERS
PHILIPPE LANGELLA ARJAN NARBAD CAROLINE CHILDS Research Director, Laboratory Quadram Institute Lecturer in Nutritional of Commensals and Sciences, University of Probiotics-Host Interactions, Southampton INRA, France
ANITA FRAUWALLNER JASON BUSH LYDIA MAPSTONE CEO, Institut Allergosan Adjunct Professor, CEO, BoobyBiome Department of Biology, Brandon University, USA
SHAHRAM LAVASANI MIKE ROGERS Founder & CEO, SATU PEKKALA CEO, TrooFoods ImmuneBiotech Academy of Finland Research Fellow, Adjunct professor, University of Jyväskylä AUBREY LEVITT DAVID KYLE CEO, Postbiotics+ Chairman and CSO, Evolve PAULO REFINETTI Biosystems CEO and Founder of REM Analytics AARON DEL DUCA MARIO GUSLANDI JEAN-POL WARZEE Head, Microbiome Platform, Consultant Gastroenterologist, DayTwo President, European Scientific S.Raffaele Hospital, Adjunct League for Probiotics - ESLP Professor of Gastroenterology, S.Raffaele University, Milan, Italy OLAF LARSEN Senior Manager Science, GRÉGORY LAMBERT GER RIJKERS Yakult Nederland B.V., CEO and VP of R&D, Associate Professor, Vrije Professor in Biomedical and TargEDys Universiteit Amsterdam Life Sciences, University of Roosevelt, The Netherlands MONIKA SCHAUBECK Nutritional Scientist, Team MARK O’MAHONY MIGUEL GUEIMONDE Science, Department Research Technology Scout (Devices & FERNÁNDEZ and Development, HiPP Diagnostics), Walgreen Boots Research Scientist, IPLA-CSIC Alliance
MARIA JENMALM YEMI ADESOKAN Professor of Experimental Co-Founder and CSO, Allergology, Linkoping GNUbiotics University
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 SKIN & TOOLS & TECHNOLOGY SPEAKERS
THOMAS DAWSON MIKE HOPTROFF LIONEL BRETON Senior Principal Investigator, Senior R&D Manager, Unilever Scientific Director, L'Oréal Skin Research Institute Advanced Research Singapore, Agency for Science, Technology and Research and Affiliated Professor, Department MIRCEA PODAR of Drug Discovery, School of Pharmacy, Distinguished Scientist and RADHIKA BONGONI Medical University of South Carolina, USA Group Leader, Systems Business Developer, Genetics, Oak Ridge National BaseClear B.V. CATH O’NEILL Laboratory Professor of Translational Dermatology, University MARK WEBBER of Manchester and CSO, Group Leader, Quadram IHAB BOULAS SkinBiotherapeutics plc. Institute Former CEO, Unibiome
INGMAR CLAES CSO, Yun Probiotherapy MATTHEW GERDING VERONIKA OUDOVA Investigator II, Novartis Institute Co-Founder, S-Biomedic, for BioMedical Research (NIBR) Belgium
MIREILLE VEGA VGAM Biosciences, Bridging LEO MELCHERS INGE LINDSETH Life and Science Strategic Partnerships, Expert Nutrition, Biosortia Pharmaceuticals MyMicrobiome
ALEX CHAPMAN Head of Operations, Labskin ARNE MATERNA JONATHAN Vice President of Product, FRIEDMAN CosmosID Senior Lecturer, Department of Plant Pathology and JENNIFER POWERS Microbiology, Hebrew PIM GAL Assistant Professor of University, Israel Senior Clinical Scientist, Centre Dermatology, University of for Human Drug Research Iowa, USA JOHAN BENGTSSON (CHDR), The Netherlands PALME Assistant Professor, Centre MILANA ANASH SØREN KJAERULFF for Antibiotic Resistance CEO, Founder, ClearSkin CEO, Lactobio Research, Institute of Biomedicine, University of Gothenburg, Sweden
SENIOR CHRISTINE LANG REPRESENTATIVE Chief Scientific Officer, Clinical Microbiomics Belano Medical AG
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
08:20-08:50 Room: Shipping Hall Registration & Refreshments
MICROBIOME R&D & BUSINESS COLLABORATION PROBIOTICS & PREBIOTICS SKIN & COSMECEUTICALS Room: Diamond Room I&II Room: Goudriaan room I&II Room: Leeuwen room I&II
Global Engage Welcome Address and Morning Chair’s Global Engage Welcome Address and Morning Chair’s Global Engage Welcome Address and Morning Chair’s Opening Remarks Opening Remarks Opening Remarks KEYNOTE ADDRESS: KEYNOTE ADDRESS: KEYNOTE ADDRESS: KAREN NELSON PHILIPPE LANGELLA THOMAS DAWSON President, J. Craig Venter Institute, USA Research Director, Laboratory of Commensals Senior Principal Investigator, Skin Research and Probiotics-Host Interactions, INRA, France Institute Singapore, Agency for Science, Technology and Research and Affiliated Professor, Department of Drug Discovery, School of Pharmacy, Medical University of South Carolina, USA 09:00-09:40 09:00-09:40 09:00-09:40 Role of eukaryotic microflora in skin disease and skin health homeostasis The vast majority of “microbiome” data remains “bacteriome”. In human skin, the mycobiome is a key player which cannot be ignored. The distribution of fungal DNA, the size of fungal cells (biomass per genome), immunological profiling (and the Il-17 response), and clinical treatment indicate that fungi are a key aspect of healthy skin homeostasis and are ignored at the researchers peril. We have shown significant differences in the composition of skin microbiome related to geography and ethnicity, and are building Asia specific data to enable modulation of the skin microbiome to improve skin health. PAUL WILMES MARIO GUSLANDI CATH O’NEILL Associate Professor of Systems Ecology, Consultant Gastroenterologist, S.Raffaele Hospital, Professor of Translational Dermatology, University University of Luxembourg Adjunct Professor of Gastroenterology, S.Raffaele of Manchester and CSO, SkinBiotherapeutics plc. Systems ecology of host-microbiome University, Milan, Italy Lactobacilli in topical products: choosing the interactions Treating chronic intestinal disorders with right species for the job • Integrated multi-omics of microbiome samples probiotics Lactobacilli have been used in cosmetic products for years. In • Different functions expressed in health compared to disease Probiotics are potentially helpful in chronic intestinal disorders, this presentation, I will explore the different activities of various • Mechanistic understanding of causal relationships where there is an imbalanced composition of the gut microbiota species of lactobacilli and show why the ‘right species for the (dysbiosis). This applies, for instance, to irritable bowel syndrome right job’ should be used. In particular, I will describe my work
09:40-10:10 09:40-10:10 (IBS) and symptomatic, uncomplicated diverticular disease (SUDD). 09:40-10:10 using lysates from L. rhamnosus GG to improve skin barrier IBS is a multi-factorial condition the symptoms of which can be function, showing development of this from basic studies in the partially related to dysbiosis (reduced fecal amount of Lactobacilli, laboratory, to a clinical study. Bifidobacteria and F.prausnitzii). Although trials with probiotics have employed different products and doses, various meta- analyses have concluded that probiotics as a group (especially Bifidobacteria )are useful in ameliorating symptoms. SUDD is largely depending on the gut microbiota. An increase in the amount and in the diversity of Enterobacteriacee have been described,while different types of dysbiosis are linked to different symptoms. Open studies suggest that probiotics may help to prevent development of acute diverticulitis, but controlled trials are lacking. On the other hand controlled studies with probiotics + mesalazine indicate a superior efficacy over the single agents and placebo.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
10:10-10:40 ARNE MATERNA 10:10-10:40 10:10-10:40 CHRISTINE LANG Vice President of Product, CosmosID 30-Minute Solution Provider Presentation Chief Scientific Officer, Belano Medical AG For sponsorship opportunities please contact Gavin Hambrook at [email protected] / +44 (0) 1865 849841
10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Odd Numbered Poster Presentations
Room: Diamond Room I&II Room: Van Oldenbarnevelt Room Room: Goudriaan room I&II Room: Leeuwen room I&II
IBD, COLITIS, METABOLIC DISEASES WOMEN’S HEALTH PROBIOTICS & PREBIOTICS SKIN & COSMECEUTICALS SANDRINE CLAUS LIISA LEHTORANTA SHAHRAM LAVASANI INGMAR CLAES CSO, LNC Therapeutics R&D Manager, Nutrition & Founder & CEO, ImmuneBiotech CSO, Yun Probiotherapy Restoring gut Microbiome Biosciences, DuPont Targeting the brain- A topical cream with functions using keystone single Vaginal Microbiota gut-microbiome axis by encapsulated ‘live’ strain bacteria in the treatment Management and Impact on ImmuneBioticsTM, a new lactobacilli clinically of metabolic disorders Women’s Health therapeutic avenue for management of improve acne symptoms
11:50-12:15 Gut microbiome dysbiosis is associated with a 11:50-12:15 • Outline the importance of vaginal 11:50-12:15 autoimmunity 11:50-12:15 • New dermatological approach to antibiotics number of metabolic disorders, such as obesity microbiota on health • Brain-gut-microbiome axis; potential in reducing acne symptoms – positioning and related co-morbidities. In situations where • Overview of current and future trends on therapeutic targets and probiotic treatments within acne guidelines a causal link between specific microbes and vaginal microbiota research • Designing multi-targeted therapeutic • Selection of Lactobacillus strains to important phenotypic traits has been established, • Explore the ways how to beneficially modulate microbial consortium; translational success beneficially impact the skin microbiota it makes sense to use a microbiome-based vaginal microbiota to improve health for GutMagnificTM in management of IBS • YUN’s encapsulation technology ensuring therapeutic strategy to restore altered or missing • ImmuneBioticsTM, new generation of the viability of beneficial bacteria in water functions. Here we will discuss how using probiotic products designed to boost the based formulations rationally selected keystone single strain bacteria immunotherapy treatments • Case studies of use of live lactobacilli in can be used as a novel therapeutic approach. other dermatological conditions
RIKKE NIELSEN DUCCIO CAVALIERI CAROLINE CHILDS SABRINA LEOTY-OKOMBI (Reserved) CEO and Founder, Beo Professor of Microbiology, Lecturer in Nutritional Sciences, R&D Project Leader, BASF Therapeutics University of Florence University of Southampton Topic: Healthy Skin Microbial treatments for gout Beyond the bacteriome – vaginal and gut Probiotics, prebiotics and the 12:15-12:40 12:15-12:40 12:15-12:40 12:15-12:40 and metabolic diseases mycobiome and inflammatory balance immune system • Screening and lead selection of microbial • How does the gut microbiota interact with therapy for hyperuricemia the development of the immune system, • Pre-clinical development, biomarkers and particularly during early life? translation into the clinic • The leaky gut – causes and consequences • Product classes and commercialisation of • The role of nutrition in directly modulating microbiome therapies the immune system FLORENCE SEJOURNE MARIE DRAGO AUBREY LEVITT MIREILLE VEGA CEO, Da Volterra Founder, Gallinée CEO, Postbiotics+ Founder, VGAM Biosciences Protecting and preserving Topic: Vaginal Microbiome Postbiotics, why we believe Optimized Growth Medium for a Healthy 12:40-13:05 12:40-13:05 12:40-13:05 the intestinal microbiota from they are probiotics 2.0 12:40-13:05 Skin Microbiota: a balanced review of antibiotic-induced dysbiosis • Our clinical research, from prebiotic and postbiotic approaches with an antibiotic quencher: an effective metabolites to gut modeling to in the clinics and safe solution for the prevention of with patients Clostridioides difficile infection • What are postbiotics and why they are • DAV132, a microbiota protective therapy that important quenches the impact antibiotic residues in • How postbiotics enhance probiotics
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
the colon, is able to preserve the intestinal • Why postbiotics have the potential to be microbiota, in a Phase 2 clinical study utilized as adjunct therapies
12:40-13:05 conducted in 260 patients 12:40-13:05 12:40-13:05 12:40-13:05 • The understanding of DAV132 profile in humans is reinforced by a series of studies in Continue Continue healthy subjects including microbiome analysis • Additional animal model translation work will also be presented HENRIK YUANYUAN ALEX BJØRN CHEN CHAPMAN NIELSEN Sales Director, Novogene Head of Operations, Labskin CSO, Advanced sequencing solutions Labskin-AI, a Human Ultrahigh resolution for microbiome studies Skin Equivalent for the microbiomics and integrative Novogene is the leading global NGS service Investigation of Skin Dysbiosis systems biology provider. In this talk we will introduce Labskin is a full thickness human skin model. Clinical-Microbiomics offers custom-tailored Novogene's experience and technologies in The Labskin epidermis has a dry surface microbiome research as a service, including helping researchers with microbiome studies. with an effective barrier function that allows data-generation and bioinformatics analysis. colonisation by human skin microflora
13:05-13:35 Here we present our framework for ultra- (individual commensal and pathogens, 13:05-13:35 13:05-13:35 30 Minute Solution Provider Presentation 13:05-13:35 high resolution (UHR) microbiomics. UHR For sponsorship opportunities please contact microbial consortia and whole microbiomes microbiomics allows us to accurately profile Gavin Hambrook at isolated from volunteers). This allows us to the microbial composition of samples and to [email protected] / mimic skin diseases such as acne, seborrheic build phylogenetic trees that relate sub-species +44 (0) 1865 849841 dermatitis, atopic dermatitis or psoriasis. populations across samples and subjects. We use AI technology to identify features Phylogenetic trees elegantly condense vast characterising healthy and dysbiotic skin amounts of details into simple data-structures states that can detect shifts in the microbiome that can be used for statistical analysis and for after topical treatment. Active ingredients deriving functional insights. Moreover, it allows us and formulations can be tested to study to track therapeutic strains, to monitor microbial their effects on the skin and the colonising population dynamics, and even to gain insight to microflora. We measure multiple endpoints microbial inherence of accessory genes. via viable counting, ELISA, histology & immunohistochemistry, metagenomics, proteomics and transcriptomics.
13:35-14:35 Room: Shipping Hall Lunch / One-to-One Meetings
IBD, COLITIS, METABOLIC DISEASES WOMEN’S HEALTH PROBIOTICS & PREBIOTICS SKIN & COSMECEUTICALS
POSTER COMPETITION WINNER TALKS: POSTER COMPETITION WINNER TALKS: POSTER COMPETITION WINNER TALKS: POSTER COMPETITION WINNER TALKS: 14:35-14:50 14:35-14:50 14:35-14:50 14:35-14:50 If interested in submitting a poster and/ If interested in submitting a poster and/ If interested in submitting a poster and/ If interested in submitting a poster and/ or applying to present a poster on the or applying to present a poster on the or applying to present a poster on the or applying to present a poster on the programme, please CLICK HERE and apply programme, please CLICK HERE and apply programme, please CLICK HERE and apply programme, please CLICK HERE and apply before the deadline 27th April 2020 before the deadline 27th April 2020 before the deadline 27th April 2020 before the deadline 27th April 2020
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020 14:50-15:05 SENIOR 14:50-15:05 SENIOR ARNE REPRESENTATIVE 15 Minute Solution Provider Presentation REPRESENTATIVE MATERNA For sponsorship opportunities please contact Biose Probiotical Vice President of Product, Gavin Hambrook at 14:50-15:20 [email protected] / +44 (0) 1865 849841 14:50-15:20 CosmosID 15:05-15:20 SENIOR 15:05-15:20 SENIOR REPRESENTATIVE REPRESENTATIVE Luina Bio Life and Soft
MARIA AKERMAN HANA JANEBDAR GRÉGORY LAMBERT JENNIFER POWERS Director Process R&D, Founder and CEO, Juno Bio CEO and VP of R&D, TargEDys Assistant Professor of Oxthera, Sweden Topic: Vaginal Microbiome Modulating the appetite Dermatology, University of Unlocking the potential of through the probiotic strain Iowa, USA the microbiome: Oxalobacter Hafnia alvei HA4597 Microbiome Trends in formigenes for the treatment of Primary TargEDys is a French clinical stage biotech Cutaneous Scar Formation hyperoxaluria company aiming to control metabolic disease by Chronic wounds and scars create huge • OxThera pursues the development of modulating the appetite through an intervention healthcare expenditures. There are huge Oxabact®, a live biotherapeutic drug made of on the microbiome. TargEDys’ innovative, satiety knowledge gaps related to the extent to lyophilized Oxalobacter formigenes. inducing technology (ProbioSatys®), is based on which bacteria potentiate abnormal wound • To date, OxThera has completed three a unique understanding of appetite regulation by healing. Our research seeks to explore double-blinded phase II/III clinical studies the microbiome at the molecular level. Bacteria the connection between the cutaneous with different formulations (OC3 and can send signals of satiety to the brain from the microbiome, the immune system, and clinical OC5) and are currently pursuing a fourth gut by molecularly mimicking satiety hormones, scarring outcomes with an eye towards multicenter, international, double-blinded thus activating natural satiety pathways. The basis therapeutic applications. phase III clinical trial investigating the safety of the technology is a commensal, enterobacteria and efficacy of the improved Oxabact® probiotic strain, Hafnia alvei HA4597™, that 15:20-15:45 15:20-15:45 15:20-15:45 15:20-15:45 formulation, OC5 in Primary hyperoxaluria produces the ClpB protein, a mimetic of the satiety patients with maintained renal function. hormone α-MSH. The pre-clinical data have • Confirmation of long-term efficacy and demonstrated the beneficial anti-obesity effects safety is now underway through the ongoing of Hafnia alvei 4597™ in mice. Treatment with phase III, double-blind, placebo-controlled Hafnia alvei4597™ was associated with decreased study, where subjects are being randomized body weight and fat mass gain along with 1:1 to receive either OC5 or placebo, and reduced food intake as well as positive effects on are offered to pursue a long-term follow up glycemia and OGTT. A randomised, multicentric, double-blind, placebo controlled clinical trial in study to prove clinical benefit. 240 subjects has been completed. The trial met the primary endpoint: statistical difference in the proportion of subjects who lost at least 3% of body weight at 12 weeks. Amongsts other findings, the mechanism of action is confirmed by achieving secondary endpoints such as an increase in the feeling of fulness in the verum group. This talk covers ProbioSatys’® journey from its preclinical and clinical stage to commercialized product, EnteroSatys®, including formulation, manufacturing and control. First results of clinical trial will be presented and discussed.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
EDWARD GREEN FRANCO VICARIOTTO ANITA FRAUWALLNER MICHELE EVRARD (Reserved) Chief Executive, CHAIN Specialist Obstetrics and CEO, Institut Allergosan Founder & CEO, M.E.SkinLab Biotechnology Ltd. Gynecology, Senior consultant of How high quality probiotics Title TBC Next Generation Live San PIO X Hospital Milan, Italy improve our customers´ lives Biotherapeutics The rationale of probiotics in and our companies´ healthy • CHAIN develops superior live biotherapeutic urogenital female healthcare development products based on Clostridia bacteria. The human vaginal microbiota plays an The human microbiota has become the focus • Our bacteria are precision engineered to important role in the maintenance of a of medical research in the 21st century. Pre, produce specific therapeutic molecules in woman's health, as well as of her partner pro- and synbiotic treatment is able not only the human gut. and newborns. When this predominantly to strengthen the gut barrier function, which • Our unique engineering capability supports Lactobacillus community is disrupted or ultimately restores many dysfunctions in a pipeline of therapeutic candidates decreased in abundance, Vaginitis may elderly as well as in newborns, but also is 15:45-16:10 15:45-16:10 15:45-16:10 15:45-16:10 addressing multiple disease areas occur.Of the millions of cases of vaginitis, highly effective to improve the gut-brain-axis associated with the human gut microbiome. most are caused by bacterial vaginosis (BV), which is shown in many research articles followed by Vulvovaginal candidiasis (VVC). about depression, migraine, dementia and BV is associated with ascending infections cognition. But what is good for our customers and obstetrical complications, such as is even better for those companies that chorioamnionitis and preterm delivery Therapy develop these high-quality probiotics - if they with oral or local recommended antibiotics are able to market these products in surprising is often associated with failure and high ways, targeting new groups of people which rates of recurrences. ( Antibiotics can not are interested in a modern life style. always penetrate the pathogenic biofilm) The dominance of lactobacilli in healthy vaginal microbiota and its depletion in BV and VVC has given rise to the concept of oral or vaginal use of probiotic strains for treatment and prevention of vaginitis and to prevent pregnancy disease
16:10-17:00 Room: Shipping Hall Afternoon Refreshments / One-to-One Meetings / Even Numbered Poster Presentations
IBD, COLITIS, METABOLIC DISEASES WOMEN’S HEALTH CROSS-EVENT ROUNDTABLE DISCUSSIONS SKIN & COSMECEUTICALS
17:00-17:30 17:00-17:30 17:00-17:30 17:00-17:30 SENIOR 30 Minute Solution Provider Presentation 30 Minute Solution Provider Presentation 30 Minute Solution Provider Presentation REPRESENTATIVE For sponsorship opportunities please contact For sponsorship opportunities please contact For sponsorship opportunities please contact Givaudan Gavin Hambrook at Gavin Hambrook at Gavin Hambrook at [email protected] / +44 (0) 1865 849841 [email protected] / +44 (0) 1865 849841 [email protected] / +44 (0) 1865 849841
LISA MACFARLANE RACHEL TEITELBAUM (Reserved) ROUNDTABLE SESSION: ARTEM GURIEV (Reserved) Co-Founder, The Gut Stuff CEO, Hervana Bio Roundtables are informal, small-group interactive Head of TUC SSMU, Professor, Siberian State Topic: Women’s Health discussions on key topics in the field. Discussion Medial University leaders will introduce sub-topics/questions Topic: New probiotic delivery system for 17:30-18:20 17:30-17:55 17:30-17:55 ALANA MACFARLANE 17:30-17:55 Co-Founder, The Gut Stuff for discussion and roundtable attendees are topical use How can we make the encouraged to participate actively in the session. microbiome and digestive Table 1: Microbiome friendly skincare. Are health mass market the consumers interested? In a world where the science is MARK O’MAHONY incredibly exciting, but also very Technology Scout (Devices & Diagnostics), new, how can we educate the consumer in Walgreen Boots Alliance
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
17:30-17:55 a realistic and efficacious, yet engaging way. 17:30-17:55 Table 2: Clinical trials 17:30-17:55 Equally how can we bridge the healthcare gap addressing the possible efficacy for digestive issues to get millennial thinkings Continued of probiotics in IBD Continued about prevention and wellbeing. MARIO GUSLANDI San Raffaele Scientific Institute SENIOR REPRESENTATIVE SENIOR REPRESENTATIVE MILANA ANASH Topic: IBD, Colitis, Metabolic Diseases Topic: Women’s Health Table 3: Human milk probiotics in infant CEO, Founder, ClearSkin Invitation Out Invitation Out microbiota development Topic – Skin Microbiome MONIKA SCHAUBECK Nutritional Scientist, Team Science, 17:30-18:20 Department Research and Development, HiPP Table 4: Screening, selection 17:55-18:20 17:55-18:20 17:55-18:20 and development of ingredients and formulation for their impact on skin microbiota INGMAR CLAES CSO, Yun Probiotherapy Table 5: How to overcome the limiting steps of the Biotech industry? IHAB BOULAS Consultant & former CEO, Unibiome
18:20 Chair's Closing Remarks / End of Day One
18:20-19:20 Room: Shipping Hall Networking Drinks Reception
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 1 MONDAY 18TH MAY 2020
17:30-18:20 ROUNDTABLE SESSION: Table 4: Screening, selection and development of ingredients and formulation for their impact on skin microbiota Table 1: Microbiome friendly skincare. Are the consumers interested? INGMAR CLAES MARK O’MAHONY CSO, Yun Probiotherapy Technology Scout (Devices & Diagnostics), Walgreen Boots Alliance Table 5: How to overcome the limiting steps of the Biotech Microbiome friendly skincare is beginning to hit the mainstream. industry? Previously the preserve of niche brands, bigger players are now IHAB BOULAS embracing the concept - Unilever’s brand ‘Dove’ has introduced Consultant & former CEO, Unibiome the mass market to the skin microbiome through a recent UK TV • What are the limiting steps to growth? advertising campaign focusing on their ‘microbiome gentle’ body • What inspiration to draw from other industries? washes. But is there any scientific evidence that it is necessary • Which resources and advantages are most underexploited? for cosmetic products to be microbiome friendly? Are consumers • In practice, which processes benefit the most from outsourcing? interested or even aware of their skin microbiome? And an important point to consider is that the cosmetics industry does not appear to have a consistent definition of microbiome friendly, or standard testing criteria for microbiome friendly cosmetic products. However, is it now time that everyone embraced their skin microbiome, and made an effort to protect it? Table 2: Clinical trials addressing the possible efficacy of probiotics in IBD MARIO GUSLANDI San Raffaele Scientific Institute Table 3: Human milk probiotics in infant microbiota development MONIKA SCHAUBECK Nutritional Scientist, Team Science, Department Research and Development, HiPP • Mom knows best - how human milk nurtures the infant´s microbiota • It takes guts to stay healthy - The early window of opportunity • Human milk probiotics – possibilities and potential of microorganisms from human milk
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020
08:20-09:00 Room: Shipping Hall Refreshments
MICROBIOME R&D & BUSINESS COLLABORATION PROBIOTICS & PREBIOTICS SKIN & COSMECEUTICALS Room: Diamond Room I&II Room: Goudriaan room I&II Room: Leeuwen room I&II KEYNOTE ADDRESS: KEYNOTE ADDRESS: KEYNOTE ADDRESS: EMERAN MAYER AARON DEL DUCA LIONEL BRETON Director, UCLA Head, Microbiome Platform, DayTwo Scientific Director, L'Oréal Advanced Research Topic: The role of the gut microbiota brain Topic: DayTwo’s technology, the company Harnessing the Gut Skin Brain Axis in Health interactions and activities in the microbiome space Disease – Short review of a future option There is increasing evidence suggesting that gut, brain and skin do not act as isolated organs but are involved in a straight relationship. Emerging research has shown that skin microbiota 09:00-09:40 09:00-09:40 09:00-09:40 may play a critical role at the interface of all three organs. Therefore, it is not surprising that conditions affecting one organ’s microbiota may also have manifestations in the two others. More importantly, a better understanding of the intestinal microflora and its subsequent relationship with our skin may provide new insights into developing unique product candidates that will accurately treat a spectrum of skin disease indications with current unmet needs. As the microbiome continues to enter the scientific mainstream, this multiple complexity organ is largely unexplored, some examples will be presented on gut brain skin connection in some dermatosis and how skin could be involved in some neurodegenerative disorders in the future
HOK BING THIO ARJAN NARBAD Invitation Out Erasmus University Medical Center Quadram Institute
09:40-10:10 Sleep, microbiota and immune system 09:40-10:10 09:40-10:10 • Day and night rhythm of microbiota • Chronobiological impact on microbiota and immune system • Effects of combined dietary and sleep interventions on immune system
MORTEN L. ISAKSEN INGE LINDSETH SENIOR REPRESENTATIVE Founder and CEO, Bio-Me Expert Nutrition, MyMicrobiome DSM PMP™ - A targeted approach Bringing clarity to the fragmented to microbiome profiling probiotics market – a quality standard Precision Microbiome Profiling (PMP™) was set For clinicians and consumers alike, it can be 10:10-10:40 10:10-10:40 up to deliver rapid, detailed, accurate and high throughput 10:10-10:25 challenging to choose the right probiotic. The opportunity microbiome profiling. PMP™ makes it possible to obtain to market probiotic products with specific health claims is direct quantification of the composition of 100+ of the most limited within the EU/Europe, and the quality of the products dominant and relevant bacterial species in fecal samples. The on the market is not subjected to quality control by the fully validated targeted approach is useful in running large, authorities. This can be of detriment both to clinicians and longitudinal studies and in clinical applications where speed patients, as well as to vendors who put in the resources to and reproducibility is critical for correct stratification of conduct clinical studies to document the efficacy and quality patients. The presentation will go through some of the recent of their product. The MyMicrobiome quality seal “Microbiome- data from using PMP™ in various clinical settings. Lessons friendly” can be a guidance in this respect. This presentation
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020
learnt from analysis of thousands of samples from the HUNT details the MyMicrobiome seal, and what it hopes to achieve study will also be shared. 10:10-10:25 for the probiotic industry, the health sector and the consumer. MyMicrobiome works with experts in the field and has 10:10-10:40 inhouse facilities to conduct studies of several aspects of 10:10-10:40 probiotic quality. Continued 10:25-10:40 15 Minute Solution Provider Presentation For sponsorship opportunities please contact Gavin Hambrook at [email protected] / +44 (0) 1865 849841
10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Odd Numbered Poster Presentations
Room: Diamond Room I&II Room: Van Oldenbarnevelt Room Room: Goudriaan room I&II Room: Leeuwen room I&II
GUT-BRAIN AXIS DIAGNOSTICS PERSONALISED NUTRITION SKIN & COSMECEUTICALS
ALETTA KRANEVELD FINN TERJE HEGGE JASON BUSH YUG VARMA (Reserved) Professor Interdisciplinary CTO and Head of Operations, Adjunct Professor, Department of CEO, Phi Therapeutics Translational Pharmacology, Genetic Analysis AS Biology, Brandon University, USA Topic: Skin Diseases – Acne University of Utrecht, The Transition of microbiota Microbiome biomarkers Netherlands analysis from research tool predict human health Parkinson’s disease: no guts no glory. to clinical utility improvements in response to resistant The recently reported leaky gut, intestinal The GA-map® technology represents a starch supplementation inflammation and changes in the composition unique approach to microbiome analysis. By Screening the gut microbiome for biomarkers of the microbiota in patients point to the combining information from a well-defined set can help discriminate people who stand to relevance of gut-microbiome-immune-brain of pre-determined markers it enables highly benefit from microbiome-targeting therapies axis in Parkinson’s disease. Based on (pre) reproducible and standardized information (responders) from those who do not (non- responders). In some cases, coupling prebiotic
11:50-12:15 clinical data the talk will shed some light 11:50-12:15 to be derived from the complex human gut 11:50-12:15 11:50-12:15 on the possible mechanism of the crosstalk microbiota. This information enables actionable therapy with other forms of supplementation between gut and brain in Parkinson’s disease. results such as disease progression prediction may help turn non-responders into responders. There is a great need for additional therapies and treatment response prediction. To this end, we analyzed changes in glucose, for Parkinson’s disease that reduce both cholesterol, and SCFA metabolism in motor and non-motor symptoms. A poor gut correlation with changes in bacteria in the function leads to a poor brain function and microbiomes of healthy participants consuming vice versa; therefor targeting the microbiota/ MSPrebiotic® resistant starch. We identified gut-immune axis with nutritional interventions several biomarkers that changed in correlation or pharmaceutical compounds could be a with health parameters after MSPrebiotic® new approach for the (additional) therapy of consumption, including effects on glucose neurodegenerative disorders for the treatment metabolism, cholesterol homeostasis, and of both motor and non-motor dysfunction. butyrate production. These findings highlight the potential value of coupling microbiome testing with selective microbiome interventions to reduce risk factors for disease.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020
PIERRE LESTAGE KRISTOFER COOK SATU PEKKALA VERONIKA OUDOVA CEO, Neribiom, France CEO, Carbiotix Academy of Finland Research Co-Founder, S-Biomedic, Topic: The gut-brain connection Multi-sample, longitudinal Fellow, Adjunct professor, Belgium gut health testing and the University of Jyväskylä Topic Cutibacterium acnes generation of functional gut Targeting Faecalibacterium the main component of the microbiome data prausnitzii with prebiotic xylo- skin microbiota • Understanding the natural variability of oligosaccharides (XOS) prevents from non- the gut microbiome and its impact on alcoholic fatty liver disease (NAFLD) data accuracy High liver fat content associated with low • Multi-sample, longitudinal gut health testing abundance of Faecalibacterium prausnitzii1 as a means to improve microbiome data and administration of F. prausnitzii prevented • Applications of improved microbiome data in NAFLD in mice2. Because therapeutic microbes 12:15-12:40 12:15-12:40 the F&B, nutraceutical and therapeutic space 12:15-12:40 are not always accepted to treat humans, we 12:15-12:40 sought to target F. prausnitzii with diet to treat NAFLD in rats. XOS increased F. prausnitzii in vitro and in vivo having minor effects on other gut microbes. Supplemented with high-fat diet (HFD), XOS prevented NAFLD. The underlying mechanisms involved increased hepatic β-oxidation and enhanced mitochondrial respiration. Compared to HFD, HFD+XOS decreased fecal isovalerate and tyrosine levels, metabolites previously associated with NAFLD. Isovalerate associated positively and butyrate negatively with hepatic fat. Our results identified F. prausnitzii as target to treat NAFLD. Finally, we also present a study protocol for prebiotic intervention in humans.
GUT-BRAIN AXIS BIOBANKS PERSONALISED NUTRITION SKIN & COSMECEUTICALS GEORGE TETZ SCOTT OLESEN MIKE ROGERS SØREN KJAERULFF CEO, Human Microbiology Scientific Director, OpenBiome CEO, TrooFoods CEO, Lactobio Institute The practice and promise of Story of a gut health start up through to Targeted screening of Brain microbiome promotes universal stool banks commercialization living lactic acid bacteria tau aggregation and • Stool banks centralize for skincare application, Alzheimer’s disease and standardize collection, processing, and manufacturing and formulation Here we report the first evidence for the distribution of material for fecal microbiota • Screening of lactic acid bacteria with 12:40-13:05 capacity of extracellular DNA of bacteria 12:40-13:05 transplantation (FMT). 12:40-13:05 12:40-13:05 activity against S.aureus that are known to be representatives of brain • OpenBiome, a non-profit stool bank, provides • In vitro and in vivo activity of lactic acid microbiome in patients with Alzheimer’s FMT material to clinicians treating recurrent bacteria in skincare applications disease to substantially promote tau C. difficile infection, to clinical researchers • Formulation of living lactic acid bacteria misfolding and aggregation. This study using FMT as part of clinical trials, and to basic for skincare applications suggests the new potential role of the brain scientists who need standardized, screened microbiota in the initiation and progression material for bench science and animal studies. of pathological abnormalities responsible for • Centralized stool banking can catalyze Alzheimer’s disease. research by lowering barries to conducting FMT studies and facilitating comparison of results across studies.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020
EDWIN JULIA OLAF SENIOR ABELN KAPPEL LARSEN REPRESENTATIVE Senior Business Development Customer Success Senior Manager Science, Clinical Microbiomics Manager, TNO Associate, Zymo Biomics Yakult Nederland B.V., Comprehensive analysis of the Towards a Host – Microbiome Standardizing Microbiomics – Associate Professor, Vrije skin microbiome using shotgun IBD in vitro model for the identification of Removing Bias in Collection, Universiteit Amsterdam metagenomics functional ingredients or drugs Purification and Analyses Probiotics research 2.0 • Get insights to some of the newest tools • First results of a novel in vitro IBD model will Zymo Research has the goal to provide Although the gut microbiota has been studied available for analyzing the skin microbiome. be presented researchers the best tools for microbiome intensively for the last decades, clinical trials • At Clinical Microbiomics we offer full-service • Based on combination of measurement to ensure standardized focusing on gut microbiota intervention microbiome analysis of skin samples. This 13:05-13:20 13:05-13:20 13:05-13:20 • i-screen model: 96 wells HTS model of gut microbiomic workflows. The ZymoBIOMICS™ 13:05-13:20 using probiotics are still in their infancy. includes skin-dedicated metagenomics microbiome portfolio has been developed to eliminate Probiotic products and their effects are pipelines with optimized DNA extractions, • InTESTine model: ex vivo human gut wall bias across microbiomics workflows and inherently heterogeneous, hampering a proper shotgun sequencing, and data analysis to tissue model offers a complete pipeline from start-to- comparison between clinical trials. In this maximize data quality and insights to the skin finish for all your microbiome related needs. lecture, factors underlying this heterogeneity microbiome. ZymoBIOMICS™ offers a complete workflow, will be discussed. Moreover, possible solutions • Shotgun metagenomics allows comprehensive from sample collection to analysis, which offers will be provided with respect to the design analysis of both species composition and streamlined collection, purification, and the of clinical trials to increase the success rate functional capability of the skin microbiome. first microbial community standards. for reaching statistical significance and the Using SNV-based analysis we can furthermore development of new, rationally designed, identify and discriminate strain differences of probiotic products. e.g. Staphylococcus aureus and Cutibacterium acnes between healthy subjects and people suffering from conditions such as atopic dermatitis or acne vulgaris.
13:20-14:20 Room: Shipping Hall Lunch / One-to-One Meetings OLA RADHIKA TUVESSON BONGONI Head of Process Development Business Developer, BaseClear B.V. and Support, Cobra Biologics Pre-pro-postbiotics and role in GMP Manufacturing of Live modulating our microbiome – Bacterial Therapeutics status & case studies To ensure that safe and effective treatments Microbiome makes us complete. To feed, support using Live Bacterial Therapeutic products are and maintain a balance in microbial community is brought to the patients the manufacturing thus pivotal. Therefore the use of pre, pro and post 14:20-14:50 14:20-14:35 14:20-14:50 needs to be done to the highest quality 30 Minute Solution Provider Presentation 30 Minute Solution Provider Presentation 14:20-14:35 (and many other versions) of biotics have been standards. The special characteristics of For sponsorship opportunities please contact For sponsorship opportunities please contact taking a key role in the industry for human, animal these novel products and processes brings Gavin Hambrook at [email protected] Gavin Hambrook at [email protected] and plant health. Several companies are offering challenges in manufacturing, control but also / +44 (0) 1865 849841 / +44 (0) 1865 849841 products with specific application targeting a in regulatory compliance. By choosing the health segment. Consumers should be informed correct strategy and addressing a few key on the scientific backing of such products. This elements early in the development process the presentation is a snapshot of scientific evidences risk for late failures and delays to market can put forth as case studies for the above applications. Until now the applications of these biotics has be decreased. been on disease management rather disease cure. This presentation further takes you through the state-of-art genomics technologies that might aid the quest in understanding the role-mechanism of pre-pro-postbiotics for (human) health.
MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020 14:35-14:50 14:35-14:50 14:20-14:50 FRANCOIS BIDET 14:20-14:50 SENIOR Vice-President of Business REPRESENTATIVE Development, CSP Technologies Continued Continued DNA Genotek
EARLY CAREER RESEARCHER EVELIINA MUNUKKA EARLY CAREER RESEARCHER PIM GAL PRESENTATION: Research Director, Turko PRESENTATION: Senior Clinical Scientist, Centre for Human SARITA DAM Microbiome Biobank, University PAULO REFINETTI Drug Research (CHDR), The Netherlands PhD Candidate in Translational of Turku, Finland CEO and Founder of Topical omiganan recovers dysbiosis but Psychiatry, Radboud University Turku Microbiome Biobank REM Analytics does not improve clinical mild to moderate Medical Centre Nijmegen (TMB): Could microbiome analyses and Probiotic “Drug-discovery” finding a atopic dermatitis in a phase II randomized Brain microbiome promotes tau aggregation microbial-based prevention and therapy be treatment for vulvuvaginal candidiasis controlled trial and Alzheimer’s disease part of the personalized medicine in the future? Recurent Vulvovaginal candidiasis (VVC) The impact of the gut microbiota on host • TMB (founded in 2018) aims to the is a chronic condition affecting between 5 physiology and behavior has been relatively standardized collection, preservation and and 10% of women worldwide. It is caused well established. Whether changes in microbial analyses of human microbial and microbiota by the formation of biofilms in the vagina by composition affect brain structure and function Candida yeasts. Candida are normal symbiont 14:50-15:05 samples of various types and from various 14:50-15:05 is largely elusive, however. This is important origin i.e. microbiome library of the human, and it is not its presence, but as altered brain structure and function have • Further, microbiota bio-banking enables a its behaviour that causes the disease. Using 14:50-15:05 been implicated in various neurodevelopmental 14:50-15:20 well-characterized, time-saving and proper a new tool for microbiome profile, 90 women, disorders, like attention-deficit/hyperactivity collection of fecal transplants from healthy for a total of 480 vaginal microbiome sample disorder (ADHD). We hypothesized that gut volunteers. Donors are chosen and screened have been analysed. The samples contain both microbiota of persons with and without ADHD, based on European consensus statement women affected by VVC and others that are when transplanted into mice, would differentially (Cammarota et al. 2017) and their samples not. From the analysis results it is possible to modify brain function and/or structure. are utilized in FMT procedures performed identify signatures of VVC in the microbiome. We investigated this by colonizing young, in the hospital district (recurrent C. difficile These signatures represent a first step towards male, germ-free C57BL/6JOlaHsd mice with -infection as indication) identifying targets for treatment microbiota from individuals with and without • This library of microbiota samples creates a ADHD. We generated and analyzed microbiome valuable sample resource and data pool that data, assessed brain structure and function by could be utilized in various medical research magnetic resonance imaging (MRI), and studied questions and further serve as a novel tool in mouse behavior in a behavioral test battery. personalized medicine and treatment. EARLY CAREER RESEARCHER EARLY CAREER RESEARCHER 15:05-15:20 PRESENTATION: 15:05-15:20 PRESENTATION: Invitation Out Invitation Out Topic: gut-brain axis Topic: Probiotics
PANEL DISCUSSION: CROSS EVENT ROUNDTABLE JEAN-POL WARZEE MIKE HOPTROFF Topic: Standardisation SESSION: President, European Scientific Senior R&D Manager, Unilever Roundtables are informal, small-group League for Probiotics - ESLP Product innovation and the 15:20-15:45 15:20-15:45 15:20-16:10 COLETTE SHORTT (Chair) 15:20-16:10 interactive discussions on key topics in the Probiotics quality control: skin microbiome Director Global Regulatory Affairs, field. Discussion leaders will introduce sub- the ESLP – European The increasing ability to J&J Consumer topics/questions for discussion and roundtable Scientific League for measure and characterise the human attendees are encouraged to participate Probiotics - Experience microbiome creates opportunities and actively in the session. • Numerous food supplements containing challenges for consumer product innovation Invitation to Senior Representatives x3 probiotics strains such as Lactobacilli, bought about by our developing understanding Bifidobacteria,… have been introduced in of the microbiome of human skin body and
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 2 TUESDAY 19TH MAY 2020
Table 1: Live bacteria in the Europe over the last 10 years. The beneficial our appreciation of the interplay between consumer skincare market effects of probiotics being strain specific, microbiome and skin condition. GEOFF BRIGGS not all the positive results of one strain or Technology Scout (Devices & association can be generalized to other strains. Diagnostics), Walgreen Boots • Today all parties involved agree on the need Alliance for a “Quality Label” to differentiate quality products from “non-controlled“ products. In 15:20-15:45 Recent advances in microbiome science 15:20-15:45 has led to an explosion in consumer 2019, ISAPP has co-published a document interest and probiotic technologies are about the importance of improving end-user now common across the cosmetic skincare trust in the quality of Commercial probiotic market. Live probiotics are common oral products, referring to the ESLP supplements, but there are few companies • After more than 5 years experience in Belgium, who have extended this technology to the European Scientific League for Probiotics topical skincare. The reasons for the slow ESLP Quality label internationalisation is expansion of the live probiotics in skincare taking place in function of the spontaneous include: consumer acceptance; regulatory demands coming from the different countries and safety considerations, the challenge (Italy, France, The Netherlands) test; complicated supply chain from factory to consumer; limited shelf-life; difficulty MOMO VUYISICH ANDREA NARDELLI (Reserved) and cost of generating claims; high product CSO, Viome, USA Farncombe Family Digestive Health Research price; requirements for Microbiome Friendly Systems biology approach Institute, McMaster University 15:20-16:10 15:20-16:10 probiotic and accessory products. How can towards nutritional and LBP Topic: Skin & Microbiome therapies for chronic diseases Continued we overcome these hurdles? What about the future? Companies are developing Viome has created a systems biology platform commensal species which secrete cosmetic that collects large amounts of data relevant to actives directly onto or into the skin. How will chronic diseases. We analyze human stool and this change the skincare market? blood samples with highly accurate clinical tests, and collect accurate diet and health Table 2: The microbiome, data. The platform includes machine learning probiotics and infant health and translational science. We follow a three- 15:45-16:10 YEMI ADESOKAN step process towards creating nutritional 15:45-16:10 Co-Founder and CSO, GNUbiotics therapies: 1. In our data, we identify molecular Table 3: Protecting and patterns associated with specific diseases Defending Inventions in the by performing large observational studies Microbiome Space: Challenges (typically more than 1000 participants), 2. We and Strategies use machine learning and translational science to create personalized nutrition algorithms OLGA A. PARTINGTON that modulate the gut microbiome and human Counsel, Sterne, Kessler, physiology, and 3. We perform randomized Goldstein & Fox P.L.L.C. controlled trials to demonstrate that our Table 4: Infant gut microbiome algorithms can shift the gut microbiome and in term and preterm infants human physiology from disease to health, DAVID KYLE while positively affecting the symptoms. We Chairman and CSO, Evolve have utilized our platform for several diseases/ Biosystems conditions, and will show progress.
16:10 Chair's Closing Remarks / End of Day Two
16:10-17:10 Room: Shipping Hall Evening Activity
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 3 WEDNESDAY 20TH MAY 2020
08:20-09:00 Room: Shipping Hall Refreshments
MICROBIOME R&D & BUSINESS COLLABORATION PROBIOTICS & PREBIOTICS TOOLS AND TECHNOLOGIES Room: Diamond Room I&II Room: Goudriaan room I&II Room: Leeuwen room I&II KEYNOTE ADDRESS: KEYNOTE ADDRESS: KEYNOTE ADDRESS: QUN WANG MARIA JENMALM MIRCEA PODAR Primary Reviewer, Office of Vaccines Research and Review Professor of Experimental Allergology, Distinguished Scientist and Group Leader, Center for Biologics Evaluation and Research, U. S. Food and Linkoping University Systems Genetics, Oak Ridge National Laboratory Drug Administration The role of the infant gut microbiota in Targeted reverse genomics for isolating and Regulatory Aspects of Microbiome-Related Biologic Products shaping immune and allergy development cultivating the human microbial “dark matter” during childhood A large fraction of the microorganisms that constitute the human The increasing allergy prevalence in affluent countries may be microbiome have remained uncultured. Cultivation is important 09:00-09:40 09:00-09:40 caused by reduced intensity and diversity of microbial stimulation, 09:00-09:40 for studying pathogenicity mechanisms, for assessing potential resulting in an abnormal postnatal immune maturation. The gut beneficial effects and for understanding how microbes interact microbiota is quantitatively the most important source of microbial with each other and with their human host. We designed an stimulation and may provide a primary signal for appropriate approach based on genomic information generated by culture- immune development, in line with variations in composition and independent studies to selectively target, isolate and culture diversity in the first months of life being associated with subsequent specific organisms from the human microbiome. Antibodies were allergy development. The maternal microbial environment engineered to bind to predicted membrane proteins, followed during pregnancy may also be important in childhood immune by isolation of target cells using flow cytometry cell sorting. This programming, and a combined pre- and postnatal supplementation led to the cultivation of several Saccharibacteria and associated seems to be crucial for the preventive effect of probiotics on infant actinobacteria. Such targeted, genomics-driven strategies eczema. Probiotic interventions have so far failed to prevent asthma, for cultivation will help identifying microbial health-disease however, and further studies are required to identify efficacious determinants and preserving the human microbiome diversity. asthma and allergy preventive strategies.
Room: Diamond Room I&II Room: Van Oldenbarnevelt Room Room: Goudriaan room I&II Room: Leeuwen room I&II
BUSINESS COLLABORATION - CANCER EARLY LIFE AND INFANT TOOLS AND TECHNOLOGIES REGULATIONS AND INVESTMENT ROMAIN DAILLÈRE LARS ENGSTRAND GER RIJKERS MARK WEBBER Head of Preclinical Research, Professor, Director Clinical Genomics Facility & Professor in Biomedical and Group Leader, Quadram EverImmune Centre for Translational Microbiome Research, Life Sciences, University of Institute Improving cancer treatment Karolinska Instituet, Sweden Roosevelt, The Netherlands Rationale design of improved through Oncobax-based Topic: Successful collaborations between Topic: Setting the stage for probiotics and microbiome therapeutics academia and companies in GI-related long and healthy life therapeutics • Intestinal commensals dictate our systemic disorders, reproductive medicine and cancer • Modifying bacterial communities is
9:40-10:10 and anticancer immunity 9:40-10:10 9:40-10:10 9:40-10:10 crucial to make targeted improvements to • Harnessing the microbiome for the discovery health, currently selection of probiotics or of diagnosis and therapeutic tools in cancer microbiota interventions is based on trial is key for modulating the clinical outcome of and error. anticancer regimens • We have developed a new functional • EverImmune is developing Oncobax-based genomics tool “TraDIS-Xpress” which therapeutics to improve the efficacy of allows all bacterial genes to be tested for anticancer treatments importance in any condition. • This allows rational selection of strains with improved performance in microbiome (and other) applications.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 3 WEDNESDAY 20TH MAY 2020
BENJAMIN LELOUVIER CSO, Vaiomer The blood microbiome: new source of biomarkers for infectious and cardiometabolic diseases Thanks to optimized 16S qPCR and 16S metagenomic sequencing pipelines, Vaiomer can analyzed quantitatively and qualitatively
10:10-10:25 blood and tissue microbiome. Vaiomer has demonstrated the existence of a highly diversified
blood microbiome in healthy human donors and 10:10-10:40 10:10-10:40 10:10-10:40 shown the associations between changes in the 30 Minute Solution Provider Presentation 30 Minute Solution Provider Presentation 30 Minute Solution Provider Presentation blood microbiome and different non-infectious For sponsorship opportunities please contact For sponsorship opportunities please contact For sponsorship opportunities please contact Gavin Hambrook at Gavin Hambrook at Gavin Hambrook at diseases. This associations help to understand [email protected] / +44 (0) 1865 849841 [email protected] / +44 (0) 1865 849841 [email protected] / +44 (0) 1865 849841 the role of bacterial translocation in the diseases and find new source of diagnosis and companion biomarkers. These assays were primarily designed to analyze bacterial DNA in blood and tissue of healthy donors and therefore their signal to noise ratios are high and they are also capable of detecting and characterize bacterial infection in patients sample with really high sensitivity. 10:25-10:40 15 Minute Solution Provider Presentation For sponsorship opportunities please contact Gavin Hambrook at [email protected] / +44 (0) 1865 849841
10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Even Numbered Poster Presentations DAVID HUGHES KRISTIN MIGUEL GUEIMONDE FERNÁNDEZ MATTHEW GERDING Assistant Professor of Cancer WANNERBERGER Research Scientist, IPLA-CSIC Investigator II, Novartis Institute for BioMedical Epidemiology, UCD Conway Director R&D Alliance Establishment of the gut microbiome in Research (NIBR) Institute, University College Management, Ferring early life: A target for promoting later health Microbiome derived Therapeutics a new Dublin, Ireland Pharmaceuticals, Switzerland • The gut microbiota plays a key role in the class of drugs Immune responses to bacterial antigens and Microbiome Alliances in Ferring maintenance of human health and, therefore, • Current approaches to develop microbiome association with colorectal cancer risk in a • CTMR- collaboration with the Karolinska the microbial colonization of the newborn therapeutics 11:50-12:15 11:50-12:15 11:50-12:15 11:50-12:15 large European cohort study Institutet Stockholm, Sweden poses important implications for later health, • Challenges involved in developing Gut microbiome dysbiosis is increasingly • Bacteriophages collaborations with accumulating evidence supporting microbiome therapeutics implicated in colorectal cancer (CRC) aetiology. the key role of the neonatal period for the • Future of microbiome therapeutics However, there is a lack of prospective data microbiota-induced maturation of the host. on the potential association of candidate • The initial establishment of the microbiome carcinogenic microbes with CRC development and its further development are affected by risk. We measured antibody responses several factors. Unfortunately, our knowledge in a multiplex assay of 44 antigens from on this early process is still limited. Thus Streptococcus gallolyticus, Fusobacterium understanding the development of the nucleatum, Helicobacter pylori, pks+Escherichia microbiota in infants is of critical importance.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 3 WEDNESDAY 20TH MAY 2020
coli (expressing colibactin), and enterotoxigenic • Understanding the establishment of the Bacteroides fragilis in serum samples taken microbiome in early life promises allowing the before cancer diagnosis. Tested subjects development of intervention strategies, such were from a cohort of 492 CRC cases and as the use of probiotics and/or prebiotics, for 11:50-12:15 11:50-12:15 492 matched controls nested in the European 11:50-12:15 assisting the process of establishment of the 11:50-12:15 Prospective Investigation into Cancer and Continued microbiome to reduce the later risk of disease. Continued Nutrition (EPIC). Antibody responses to antigens of S. gallolyticus, H. pylori, plus E. coli and B. fragilis in combination were significantly associated with CRC risk, while those to F. nucleatum were not linked to CRC development. CROSS EVENT PANEL DISCUSSION: DAVID KYLE JONATHAN FRIEDMAN ROUNDTABLE SESSION: Investment - TBC Chairman and CSO, Senior Lecturer, Department of Roundtables are informal, small-group interactive MALCOLM KENDALL Evolve Biosystems Plant Pathology and Microbiology, discussions on key topics in the field. Discussion Co-Founder & CEO, Microbiome Topic: The Natural Symbiosis Hebrew University, Israel leaders will introduce sub-topics/questions Insights, Inc Between B. infantis and HMO High-throughput screening for for discussion and roundtable attendees are Provides Colonization Protection beneficial synthetic microbial communities encouraged to participate actively in the session. for the Early Infant Gut • High-throughput screening can be a powerful tool for generating beneficial 12:15-12:40 Table 1: The microbiome and ERIC DE LA FORTELLE 12:15-12:40 women’s fertility Venture Partner, microbial communities, but is currently NICOLETTA DI SIMONE Seventure Partners technically challenging. • We have developed a nanodroplet based Professor Obstetrics and platform for easy and rapid screening Gynecology, Catholic University, ~100,000 randomly-assembled microbial Rome, Italy communities. • Gut Microbiota - Researches have • Our platform can be adopted for numerous suggested a classification of people in three applications across basic and applied different classes of microbial enterotypes,
12:15-13:05 12:15-13:05 microbial ecology including pathogen characterized by specific digestive functions. suppression, pollutant degradation, and This classification might have the potential production of valuable natural products. to be clinically useful as an indicator of the risk of susceptibility in developing diseases. YEMI ADESOKAN LEO MELCHERS • Vaginal Microbiota - Recent studies Co-Founder and CSO, Strategic Partnerships, Biosortia have shown reduced Lactobacilli and an GNUbiotics Pharmaceuticals increased bacterial diversity in patients HMOs: Functionality through Small Molecule Mining of with preterm birth. These observations Diversity, Natures Way the Aquatic Microbiome for suggest that early vaginal cultures, that Therapeutics & Agriculture show absence of Lactobacillus and a
12:40-13:05 12:40-13:05 • Technological breakthroughs now polymicrobial vaginal colonization, might be allow obtaining natural microbiome and risk factors for obstetrical complications. • Endometrial microbiota. It regulates interrogating the actual hidden chemistry the activity of endometrial immune along with genomics data. cells influencing embryo implantation, • Current and advancing technologies simplify extravillous trophoblast migration and the mining of a complex mixture of signaling spiral arteries remodeling. Therefore a small molecules of the aquatic microbiome. classification based on bacterial patterns • Therapeutic and Agricultural opportunities would be useful to develop a microbiota- emerging from natural environmental based diagnosis, personalized therapies microbiome habitats. and personalized treatments
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 3 WEDNESDAY 20TH MAY 2020
Table 2: Bio-banking of microbial/microbiota & Personalised bacterial therapy based on bio-banking - TBC EVELIINA MUNUKKA Research Director, Microbiome Biobank, University of Turku 12:40-13:05 12:40-13:05 12:15-13:05 Table 3: Sleep, microbiota and 12:15-13:05 immune system - TBC Continued Continued Continued HOK BING THIO Erasmus University Medical Center Table 4: Title TBC ROBERTO GRAU Assistant Professor, School of Biochemistry and Pharmacy, National University of Rosario, Argentina
13:05-14:05 Room: Shipping Hall Lunch / One-to-One Meetings KAITLIN WADE SIMONE MACCAFERRI LYDIA MAPSTONE JOHAN BENGTSSON Elizabeth Blackwell Institute Senior Research Advisor, CEO, BoobyBiome PALME Research Fellow in Integrative Bioeconomy - Research and The breast milk microbiome: Assistant Professor, Centre for Epidemiology, University of Competitive Funding Division, Community dynamics and Antibiotic Resistance Research, Bristol, UK Alma Mater Studiorum cultivability of keystone Institute of Biomedicine, University Application of human genetics to Università di Bologna, Italy microbial species to improve of Gothenburg, Sweden understand the causal link between the gut Exploiting the microbiomes: research preterm health Deciphering the genetic mechanisms behind microbiome and colorectal cancer policies and funding to translate innovation Human breast milk harbours a diverse and microbial interactions in microbiomes Recent studies provide evidence supporting into practice unique community of microbes, which play The great complexity of microbial communities an association between the human gut • Overview of the main funding opportunities a major role in seeding the early stage infant makes it nearly impossible to identify the microbiome and colorectal cancer (CRC). related to microbiome in EU research funding gut microbiome. The ability to select keystone mechanisms behind interactions between However, few findings have translated between framework and showcase of major actions species from milk will be assessed, which their players. Akin to how model systems 14:05-14:30 14:05-14:30 model organisms and human studies have and strategies currently ongoing in the field 14:05-14:30 will inform probiotic design. This will be 14:05-14:30 such as Escherichia coli have driven our been unconvincing in their ability to offer • How to ensure faciitation for industrial important for infants without access to breast understanding of biology also outside of these causal evidence. Mendelian randomization exploitation of results milk, who are prone to microbiome linked specific models, simplified model communities (MR) is a method that uses human genetic • Microbiome in the context of the European disease. BoobyBiome is designing a probiotic can help us decipher the genetic basis of variants as instruments to proxy for a clinically Bioeconomy Strategy: the role of policy supplement for infants that will contain microbial interactions. Recent model community relevant trait to improve causal inference. We instruments to foster the future of clinically designed bacterial strains based development and rapid advancement of used MR to interrogate the causal impact of microbiome research on our findings from examining human milk large-scale technologies for studying their the gut microbiome on CRC combining data microbial communities. genes are now finally lending us insights from the Flemish Gut Flora Project and two into community interactions. In this talk, I German cohorts (n=3890) with the Genetics will specifically highlight how we use model and Epidemiology of Colorectal Cancer community systems and large-scale sequencing Consortium (n=120328). We found evidence approaches to understand the genetic basis of that presence of a genus within a certain order community stability and the ability to invade of bacteria increased the risk of CRC by 8% microbial communities. The results have impact (95% CI: 2-15%; P=0.02). on our understanding of human dysbiosis and its links to various diffuse diseases.
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 CONGRESS SCHEDULE DAY 3 WEDNESDAY 20TH MAY 2020
SENIOR REPRESENTATIVE (Reserved) OLGA A. PARTINGTON GREGORY BUCK IHAB BOULAS Merck Counsel, Sterne, Kessler, Professor, Microbiology & Former CEO, Unibiome Topic: The human microbiome and cancer Goldstein & Fox P.L.L.C. Immunology & Computer Unknown tools to increase Protecting and Defending Science, Virginia profits overnight Inventions in the Microbiome Commonwealth University • By ignoring a number of Space: Challenges and The microbiome of the female reproductive powerful tools, companies Strategies tract, pregnancy and women’s health operate sub-optimally A robust and defensible intellectual property The microbiome of the female reproductive • How to find a needle in a haystack (IP) estate can be the cornerstone of an tract has a significant impact on women’s • How to alleviate logistic burden innovative company's value. As businesses health and pregnancy. Generally thought of operating in the microbiome space move as being dominated largely by Lactobacillus 14:30-14:55 14:30-14:55 more into mainstream commerce, a proactive 14:30-14:55 species, it is becoming increasing obvious 14:30-14:55 approach to IP protection is imperative. that the healthy female vaginal microbiome Strategies for patent protection in this space can be quite complex. Hallmarks of a healthy can differ from the traditional small-molecule- reproductive tract vary across racial and and antibodies-based inventions. In addition, socioeconomic borders in ways that are the choice between patent protection only now becoming clearer. In pregnancy, versus trade secret can make or break the the microbiome of the female reproductive company’s IP value. This talk will address the tract seems to change in population specific unique challenges and nuanced strategies patterns across trimesters, and early associated with obtaining IP protection in microbiome-associated biomarkers may the microbiome space in the United States. become predictors of adverse pregnancy The discussion will also provide strategies for outcomes, including but not limited to preterm obtaining patent portfolios better positioned birth. These studies may lead to new strategies to withstand the scrutiny of inevitable post- for intervention and reduce the burden of an issuance challenges. less favorable vaginal microbiome on women’s health and well-being.
SENIOR REPRESENTATIVE COLETTE SHORTT FRANCESCO SAVINO (Reserved) SANJAY VASHEE (Reserved) 14:55-15:20 Topic: Cancer & the Microbiome 14:55-15:20 Director Global Regulatory 14:55-15:20 Department of Pediatrics, Universitaria Città 14:55-15:20 Associate Professor, J. Craig Venter Institute Invitation Out Affairs, J&J Consumer della Salute e della Scienza di Torino Italy Topic: Tools and Technologies for successful Considerations for Nutritional Topic: Early Life and Infant Microbiome research Microbiome Products • Regulations
15:20 Conference Close
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 POSTER PRESENTATIONS
MAKING A POSTER PRESENTATION
Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.
In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). There is no charge to any attendee to present a poster.
POSTER COMPETITION – CLOSING DATE 27TH APRIL 2020
• Submit your entry prior to the closing deadline (1 entry per person) • Four Entries for the Microbiome and Probiotics R&D and Collaboration Forum will be selected by the judges • The winners of the poster competition will be given a 15-minute speaking position on the conference agenda and notified in advance of the meeting • The judge(s) will make the decision based on the abstract(s) submitted • Each winner will also receive a certificate from the organisers • Representatives from solution provider organisations are not eligible to enter the competition but are welcome to present posters at the meeting as normal
Submission instructions
We will require the form (downloadable below) to be submitted by the 27th April to enter the competition. To simply have your poster at the meeting, submissions must be made no later than 1st May. This is the formal deadline however space is another limiting factor so early application is recommended. Therefore please contact us with any questions you have as soon as possible. www.global-engage.com/wp-content/uploads/2019/12/MRAD20-Poster-Abstract-Submission-Form.docx VENUE INFORMATION
Postillion Convention Centre WTC Rotterdam Parkeergarage Beurs-WTC, Rodezand 19, 3011 AM Rotterdam www.postillionhotels.com/en-gb/conferenties-events/rotterdam-convention-centre In the vibrant heart of the Rotterdam metropolis: you cannot get more central than this. Wherever you are in the world, a World Trade Center is a special place. It is an (inter)national corporate community, in a unique building that meets the highest standards. From high-spec office space to high-tech meeting rooms, shops, restaurants and a wide range of additional services. • A non-stop high-speed train runs between Rotterdam and Schiphol (Amsterdam airport) every 20 minutes. The journey time is 20 minutes. Cost €22 Euros • Located in the city centre (surrounded by shops, architecture, museums, restaurants and the Port of Rotterdam) • Walking distance from the international train station • Rotterdam – The Hague airport with flights to at least 30 international destinations is a short taxi ride • A large number of parking facilities can be found in the area • A wide variety of hotels are within walking distance. (Details will be • sent to you in your welcome letter when you register)
7TH MICROBIOME AND PROBIOTICS R&D & BUSINESS COLLABORATION FORUM: EUROPE 2020 DON’T DELAY, BOOK YOUR PLACE TODAY! Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today to reserve your place at Global Engage’s 7th Microbiome & Probiotics R&D and Business Collaboration Forum: Europe 2020, with congresses featuring Microbiome, Probiotics and Skin Microbiome and Cosmeceuticals on the 18th-20th May 2020, Rotterdam, The Netherlands.
PHONE BOOKING +44 (0) 1865 671957 ext. 207 [email protected] Our conference team will make all the necessary arrangements.
ONLINE BOOKING Visit the website to book your place www.global-engage.com/event/microbiota/#register
THE CONGRESS PACKAGE INCLUDES: All Conference Sessions Lunches and Refreshments Access to Exhibition Room Networking Drinks Reception Conference Workbook E-Document Pack
HOTEL ACCOMMODATION Hotel accommodation will be available at a group rate.
FREE NEWSLETTER For updates on the 7th Microbiome & Probiotics R&D and Business Collaboration Forum: Europe 2020, plus free resources and reports, as and when our speakers authorise their release dates, check for updates at: www.global-engage.com/event/microbiota
SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE For more details contact Gavin Hambrook at [email protected] or call +44 (0) 7538 368 764
T: +44 (0) 1865 849841 E: [email protected] www.global-engage.com Follow Us
Global Engage Ltd., The Kidlington Centre, Kidlington, Oxford, OX5 2DL, United Kingdom